Related Experiment Video
Updated: Oct 27, 2025

Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field
Published on: March 16, 2019
Comparative efficacy and safety of late surfactant preparations: a retrospective study
Morgan D Lane1, Sujata Kishnani1, Obianuju Udemadu1
1Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Objective:
Characterize the use, efficacy, and safety of poractant alfa and calfactant surfactants compared to beractant in preterm infants receiving late surfactant.
Study Design:
We included infants <37 weeks gestational age (GA) discharged from Pediatrix Medical Group-managed neonatal intensive care units (1997-2017). Efficacy and safety outcomes of interest were analyzed.
Results:
Of 184,770 infants administered surfactant at any time, 7846 (4.23%) received late surfactant at a median (25th, 75th percentile) PNA of 8 days (3, 22); specifically, 2976 received poractant alfa (38%), 2890 beractant (37%), and 1936 calfactant (25%). We identified no significant differences in composite efficacy or safety outcomes between surfactants in the primary analysis, but 33-36 week GA infants administered poractant alfa had significantly greater odds of developing a safety event.
Conclusions:
Compared to beractant, there is no evidence of overall superior efficacy or safety of poractant alfa.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence of Drugs: Drugs with Multiple Indications
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence Data: Statistical Interpretation